Latest News by Industry
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $174.1 million in its first quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.40.
The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.97 per share.
The RNA interference drug developer posted revenue of $319.3 million in the period, also exceeding Street forecasts. Ten analysts surveyed by Zacks expected $307.5 million.
Alnylam shares have fallen 16% since the beginning of the year. The stock has climbed 40% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a ALNY">Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY